Why the study?
Does risk stratification with the CHA2DS2-VASc score improve the identification of high thromboembolic risk in patients with nonvalvular atrial fibrillation compared to the CHADS2 score?
Population
68 consecutive patients with sustained nonvalvular atrial fibrillation who had not yet received…
Comparison
Risk stratification using CHA2DS2-VASc and… vs Risk stratification using the CHADS2 score.
Design
Cohort
Follow-up
18 ± 2.35 months
Key result
The CHA2DS2-VASc score identified an additional 26 patients (43% of those requiring anticoagulation) at high risk for thromboembolic complications who would have been classified as lower risk by the CHADS2 score.
Authors
Loading...
May support preferring CHA2DS2-VASc over CHADS2 for AF risk stratification; leaves open whether this improves outcomes.
Observational (n=68)
No
Does risk stratification with the CHA2DS2-VASc score improve the identification of high thromboembolic risk in patients with nonvalvular atrial fibrillation compared to the CHADS2 score?
The CHA2DS2-VASc score effectively identifies a significant proportion of AF patients at high thromboembolic risk who would otherwise be classified as low or intermediate risk by the CHADS2 score.
Ciuruś et al. (2014) conducted an observational in Nonvalvular atrial fibrillation (n=68). CHA2DS2-VASc and HAS-BLED risk stratification vs. CHADS2 risk stratification was evaluated on Reclassification of thromboembolic risk. The CHA2DS2-VASc score identified an additional 26 patients (43% of those requiring anticoagulation) at high risk for thromboembolic complications who would have been classified as lower risk by the CHADS2 score.